Join Us at the AAN Annual Meeting April 18th – 22nd 2026
The First Positive Phase 3 Program in Essential Tremor
Visit us at Booth #2324 to learn more about the Phase 3 data on ulixacaltamide, an investigational therapy in development for the treatment of essential tremor that has received FDA Breakthrough Therapy Designation.
At the AAN Annual Meeting, explore detailed Phase 3 data and the science behind ulixacaltamide
Our team will be available to discuss the data and answer your questions.
Visit us at Booth #2324
Ulixacaltamide
| ID | Date | Time (CDT) | Title | Location (McCormick Place West) | Download |
|---|---|---|---|---|---|
| S11-004. | Sunday, April 19th 2026 | 4:06 PM–4:18 PM | Automated Quantitative Assessment of Archimedes Spirals in Essential Tremor: Development and Validation of a Regulatory-grade Digital Biomarker Pipeline for the Essential3 Program | W196b |  |
| 17-002. | Monday, April 20th 2026 | 11:45 AM–12:45 PM | Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from ESSENTIAL3 Study 1 (Parallel-Design Study) | Hall F | |
| 17-003. | Monday, April 20th 2026 | 11:45 AM–12:45 PM | Combined Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Results from the Phase 3 ESSENTIAL3 Program | Hall F | |
| PL5-001. | Tuesday, April 21st 2026 | 9:15 AM–9:30 AM | Maintenance of Response and Durability of Effect with Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 2 (Randomized Withdrawal Study) | Plenary Presentation W375de |
2026 AAN Abstract of Distinction Movement Disorders |
Epilepsy
| Tuesday, April 21 | ||||
|---|---|---|---|---|
| ID | Time (CDT) | Presentation Title | Location (McCormick Place West) | Download |
| 11-002 | 8:00 AM–9:00 AM | PAC-DEE: An Extension of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Seizure Models across Broad Developmental and Epileptic Encephalopathies | Hall F, Neighborhood 11 | |
| 11-007 | 8:00 AM–9:00 AM | High Seizure Burden and Limited Treatment Persistence in Epilepsy: Findings from the EMPOWER Observational Study and a US Real-world Claims Analysis | Hall F, Neighborhood 11 | |
| 14-004 | 8:00 AM–9:00 AM | PAC-PAIN: Application of the Praxis Analysis of Concordance Framework for Establishing the Predictive Validity of Preclinical Pain Models | Hall F, Neighborhood 14 | |
| 7-005 | 5:00 PM–6:00 PM | Evaluating the Therapeutic Potential of Emerging Precision Sodium Channel Modulators in Pain | Hall F, Neighborhood 7 | |
| S29-010 | 5:18 PM-5:30 PM | Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy | W192c | |
| Wednesday, April 22 | ||||
|---|---|---|---|---|
| ID | Time (CDT) | Presentation Title | Location (McCormick Place West) | Download |
| 11-009 | 8:00 AM–9:00 AM | Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus | Hall F, Neighborhood 11 | |
| 11-010 | 8:00 AM–9:00 AM | POWER1 – A Double-blind, Randomized, Multicenter Phase 2/3 Study Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Onset Seizures | Hall F, Neighborhood 11 | |
| 10-003 | 11:45 AM–12:45 PM | Vormatrigine Rapidly Reduces Seizures in Adults with Treatment-resistant Epilepsy: Results from the RADIANT Study | Hall F, Neighborhood 10 | |
| 10-008 | 11:45 AM–12:45 PM | Updates from the First-in-human Phase 1 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Vormatrigine in Healthy Participants | Hall F, Neighborhood 10 | |
| 10-009 | 11:45 AM–12:45 PM | EMERALD: A Phase 3, Randomized, Multi-center, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies | Hall F, Neighborhood 10 | |
| 10-010 | 11:45 AM – 12:45 PM | Efficacy and Safety of Relutrigine in Pediatric Participants with SCN2A- and SCN8A-related Developmental and Epileptic Encephalopathies: Pivotal EMBOLD Cohort 2 Study | Hall F, Neighborhood 10 | |
About Ulixacaltamide
Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity.
Ulixacaltamide is investigational and has not been approved by the FDA.